Other Clinical Trial - Isolated Liver Perfusion With Oxaliplatin

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The primary goal of this research study is to determine a safe dose for the drug oxaliplatin when delivered by isolated hepatic perfusion. The second goal of this research study is to determine if isolated hepatic perfusion with oxaliplatin can improve the efficacy of standard hepatic arterial infusional (HAI) therapy with floxuridine (FUDR)/leucovorin.

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT04062721` - Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases	Phase 1
	Recruiting	`NCT05692037` - Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases	Phase 1/Phase 2

NCT number	NCT01042691
Study type	Interventional
Source	University of Pittsburgh
Contact
Status	Completed
Phase	Phase 1
Start date	May 2003
Completion date	November 2011

Isolated Liver Perfusion With Oxaliplatin

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms